Intra-Cellular Therapies (ITCI) Misses Q4 EPS by 2c

Note: EPS may not be comparable

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q4 EPS of ($0.56), $0.02 worse than the analyst estimate of ($0.54).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold
• MotorK names Roy Toren to board as Helen Protopapas resigns